Electromyographic Study for the Help and Guidance of BoNTA Administration in the Treatment of Chronic Pelvic Floor Pain
Status:
Completed
Trial end date:
2020-04-29
Target enrollment:
Participant gender:
Summary
Chronic pelvic pain (CPP) is a common presenting complaint affecting approximately 15-40 % of
women aged 18-50 in western countries and 5-43% of women in most developing countries. It is
debilitating and has a large socio- economic impact, with a 45%reduction in work
productivity, and a 15% increase in absence from work in women with the condition. Botulinum
neurotoxin type A (BoNTA) has been suggested to improve pain in muscle spasm, its role in CPP
secondary to pelvic floor spasm has gained increasing interest. However, clinicians do not
have a diagnosis tool to evaluate the CPP and the BoNTA treatment results.
Design and develop an efficient and simple tool for the diagnosis and detection of pelvic
floor muscle (PFM) dysfunction based on superficial electromyography (EMG) and perform 25 EMG
registrations sessions in healthy patients and 25 EMG sessions in patients diagnoses with PFM
that will be treated with BoNTA to and study the EMG signal before and after BoNTA
administration.